Share on LinkedInShare on LinkedIn

ARTICLE · 22 DECEMBER 2017

Post-Priority-Date Evidence May Be Relevant To 35 U.S.C. § 112 Inquiry

Carlson, Caspers, Vandenburgh, Lindquist & Schuman, P.A.
Explore more from Carlson, Caspers, Vandenburgh, Lindquist & Schuman, P.A.

Recently, the Federal Circuit reversed a jury decision upholding the validity of two Amgen patents directed to a large genus of antibodies that reduce LDL cholesterol.

United StatesIntellectual Property
Nathan D. Louwagie
Nathan D. Louwagie

Recently, the Federal Circuit reversed a jury decision upholding the validity of two Amgen patents directed to a large genus of antibodies that reduce LDL cholesterol. Amgen et al. v. Sanofi et al., No. 2017-1480.  Defendants argued that the patents failed to satisfy the written description and enablement requirements under 35 U.S.C. § 112.  The principal error on which the Federal Circuit reversed the decision was the district court's exclusion of post-priority date evidence showing that defendants were required to perform substantial efforts in attempting to develop compounds covered by the asserted claims.

For a genus claim to meet the requirements of 35 U.S.C. § 112, a patent may disclose "a representative number of species falling within the scope of the genus[.]"  Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010).  The patents at issue provided three types of disclosures.  First, they explained that 3000 human monoclonal antibodies

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from